Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. (Q36480076)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author

Evangelos N Liberopoulos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Moses Elisaf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Sofia G Tsouli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Dimitrios N Kiortsis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Dimitri P Mikhailidis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cardiovascular Pharmacology and Therapeutics

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

1-15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16703216%20AND%20SRC:MED&resulttype=core&format=json

Bradykinin-mediated effects of ACE inhibition.

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The effects of antihypertensive therapy on haemostatic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Role of angiotensin II and endogenous vasodilators in the control of glomerular hemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Combination ACE inhibitors and angiotensin II receptor blockers for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin inhibition in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effect of Valsartan on hospitalization: results from Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The ONTARGET/TRANSCEND Trial Programme: baseline data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Dual blockade of the renin-angiotensin system in chronic renal disease: to do or not to do.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Dual renin-angiotensin system blockade at optimal doses for proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Add-on angiotensin receptor blockade with maximized ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Diagnosis and management of the metabolic syndrome in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

The choice of antihypertensive drugs in patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101

Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840601100101